<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-97797</identifier>
<setSpec>0304-5013</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Analysis of the use of misoprostol in the management of early pregnancy loss</dc:title>
<dc:description xml:lang="en">Objective. To study the use of misoprostol as an alternative management for early pregnancy loss. Materials and methods. Patients (n=109) diagnosed with early pregnancy loss between December 2009 and December 2010 were offered medical treatment with 600 mg intravaginal misoprostol or surgical curettage. Results. Ninety-two patients (84.40%) received medical treatment and 17 (15.60%) were treated surgically. Medical treatment was successful in 78 patients (84.8%). Compared with surgery, medical treatment was more painful (visual analog scale 1-10) (6.29 [2.46] vs. 4.24 [3.35]; P=.026), required fewer days of absence from work (3.0 [1.3-7.0) vs. 6.5 [4.0-14.8]; P=.007), and increased the need for painkillers (P=.014). Overall satisfaction (scale 1-10) was higher with surgery 9.33 (1.32) vs. 8.26 (1.64) P=.024. The cost of medical treatment was 123,04 euros lower per procedure. Conclusion. Medical treatment with misoprostol was successful in almost 90% of patients, with few adverse effects, a good satisfaction rate and lower cost than surgical curettage (AU)</dc:description>
<dc:creator>Gippini, Isabel</dc:creator>
<dc:creator>Cristóbal, Ignacio</dc:creator>
<dc:creator>Coronado, Pluvio</dc:creator>
<dc:creator>Díaz de Terán, Elisa</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo. Estudiar el misoprostol como alternativa en el tratamiento del aborto diferido precoz. Material y métodos. Se analiza a 109 pacientes diagnosticadas de aborto precoz en el Hospital La Zarzuela de Madrid, de diciembre de 2009 a diciembre de 2010, a las que se ofertó tratamiento médico (600 mg de misoprostol por vía intravaginal) o tratamiento quirúrgico mediante legrado. Resultados. Noventa y dos pacientes recibieron tratamiento médico y 17 fueron tratadas quirúrgicamente. El tratamiento médico se demostró eficaz en 78 casos (84,8%); tuvo mayor dolor (6,29 [2,46) vs 4,24 [3,35): p=0,026), menos días de baja, (3,0 [1,3-7,0] vs 6,5 [4,0-14,8]; p=0,007); mayor necesidad de analgesia (p=0,014) y una satisfacción global más baja (9,33 [1,32] vs 8,26 [1,64); p=0,024] que el tratamiento quirúrgico. Se obtuvo un ahorro significativo (p=0,000) de 123,04 euros por procedimiento. Conclusión. El tratamiento con misoprostol del aborto diferido presenta una tasa de éxitos cercana al 90%, con escasos efectos secundarios, con un buen grado de satisfacción y escaso coste sanitario, por lo que es una alternativa válida al legrado (AU)</dc:description>
<dc:source>Prog. obstet. ginecol. (Ed. impr.);55(3): 101-107, mar. 2012.</dc:source>
<dc:identifier>ibc-97797</dc:identifier>
<dc:title xml:lang="es">Análisis del valor del misoprostol en el tratamiento del aborto diferido</dc:title>
<dc:subject>^d331</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d50303</dc:subject>
<dc:subject>^d4150^s22074</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d50244</dc:subject>
<dc:subject>^d3496^s22045</dc:subject>
<dc:subject>^d22780</dc:subject>
<dc:subject>^d29962^s22073</dc:subject>
<dc:subject>^d29399</dc:subject>
<dc:type>article</dc:type>
<dc:date>201203</dc:date>
</metadata>
</record>
</ibecs-document>
